|
1
|
Brodeur GM: Neuroblastoma: biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maris JM and Matthay KK: Molecular biology
of neuroblastoma. J Clin Oncol. 17:2264–2279. 1999.PubMed/NCBI
|
|
3
|
Patel JH, Loboda AP, Showe MK, Showe LC
and McMahon SB: Analysis of genomic targets reveals complex
functions of MYC. Nat Rev Cancer. 4:562–568. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eilers M and Eisenman RN: Myc’s broad
reach. Genes Dev. 22:2755–2766. 2008.
|
|
5
|
Liu T, Tee AE, Porro A, et al: Activation
of tissue transglutaminase transcription by histone deacetylase
inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl
Acad Sci USA. 104:18682–18687. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marshall GM, Gherardi S, Xu N, et al:
Transcriptional upregulation of histone deacetylase 2 promotes
Myc-induced oncogenic effects. Oncogene. 29:5957–5968. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marshall GM, Liu PY, Gherardi S, et al:
SIRT1 promotes N-Myc oncogenesis through a positive feedback loop
involving the effects of MKP3 and ERK on N-Myc protein stability.
PLoS Genet. 7:e10021352011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun Y, Liu PY, Scarlett CJ, et al: Histone
deacetylase 5 blocks neuroblastoma cell differentiation by
interacting with N-Myc. Oncogene. Jul 1–2013.(Epub ahead of
print).
|
|
9
|
Liu PY, Xu N, Malyukova A, et al: The
histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death
Differ. 20:503–514. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guccione E, Martinato F, Finocchiaro G, et
al: Myc-binding-site recognition in the human genome is determined
by chromatin context. Nat Cell Biol. 8:764–770. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seward DJ, Cubberley G, Kim S, et al:
Demethylation of trimethylated histone H3 Lys4 in vivo by JARID1
JmjC proteins. Nat Struct Mol Biol. 14:240–242. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiang Y, Zhu Z, Han G, et al: JARID1B is a
histone H3 lysine 4 demethylase up-regulated in prostate cancer.
Proc Natl Acad Sci USA. 104:19226–19231. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmitz SU, Albert M, Malatesta M, et al:
Jarid1b targets genes regulating development and is involved in
neural differentiation. EMBO J. 30:4586–4600. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cellot S, Hope KJ, Chagraoui J, et al:
RNAi screen identifies Jarid1b as a major regulator of mouse HSC
activity. Blood. 122:1545–1555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu T, Liu PY, Tee AEL, et al:
Over-expression of clusterin is a resistance factor to the
anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer.
45:1846–1854. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Secombe J, Li L, Carlos L and Eisenman RN:
The Trithorax group protein Lid is a trimethyl histone H3K4
demethylase required for dMyc-induced cell growth. Genes Dev.
21:537–551. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Delmore JE, Issa GC, Lemieux ME, et al:
BET bromodomain inhibition as a therapeutic strategy to target
c-Myc. Cell. 146:904–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Banerjee C, Archin N, Michaels D, et al:
BET bromodomain inhibition as a novel strategy for reactivation of
HIV-1. J Leukoc Biol. 92:1147–1154. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ott CJ, Kopp N, Bird L, et al: BET
bromodomain inhibition targets both c-Myc and IL7R in high-risk
acute lymphoblastic leukemia. Blood. 120:2843–2852. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zuber J, Shi J, Wang E, et al: RNAi screen
identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Nature. 478:524–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roesch A, Becker B, Meyer S, et al:
Retinoblastoma-binding protein 2-homolog 1: a
retinoblastoma-binding protein downregulated in malignant
melanomas. Mod Pathol. 18:1249–1257. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roesch A, Fukunaga-Kalabis M, Schmidt EC,
et al: A temporarily distinct subpopulation of slow-cycling
melanoma cells is required for continuous tumor growth. Cell.
141:583–594. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hayami S, Yoshimatsu M, Veerakumarasivam
A, et al: Overexpression of the JmjC histone demethylase KDM5B in
human carcinogenesis: involvement in the proliferation of cancer
cells through the E2F/RB pathway. Mol Cancer. 9:592010. View Article : Google Scholar
|
|
24
|
Barrett A, Madsen B, Copier J, et al:
PLU-1 nuclear protein, which is upregulated in breast cancer, shows
restricted expression in normal human adult tissues: a new
cancer/testis antigen? Int J Cancer. 101:581–588. 2002. View Article : Google Scholar
|
|
25
|
Secombe J and Eisenman RN: The function
and regulation of the JARID1 family of histone H3 lysine 4
demethylases: the Myc connection. Cell Cycle. 6:1324–1328. 2007.
View Article : Google Scholar : PubMed/NCBI
|
